MindMaze Therapeutics to Offer Home-Based Neurorehabilitation with MindMotion Lite
MindMaze Therapeutics will expand its neurorehabilitation offerings with MindMotion Lite, a tablet-based solution for home use. The new product aims to make therapeutic activities more accessible to patients outside of clinical settings.
MindMaze Therapeutics is introducing MindMotion Lite, a new solution designed to bring its neurorehabilitation therapies into patients' homes via a tablet format. The company stated that this product will extend the availability of MindMotion's therapeutic activities beyond clinical environments.
Scheduled for release by the end of 2026, MindMotion Lite is engineered for easier deployment and aims to enhance patient engagement by allowing them to continue rehabilitation exercises in their own homes. This could potentially lead to improved recovery outcomes and adherence to treatment plans.
MindMaze Therapeutics, listed on the SIX Swiss Exchange under the ticker MMTX, specializes in scalable, precision-based neuro-therapeutics. Their technology integrates virtual reality, robotics, and data analytics for the rehabilitation of neurological conditions and injuries.
The introduction of MindMotion Lite aligns with the company's strategy to broaden access to its rehabilitation services. By providing a home-based option, MindMaze intends to offer a more flexible and continuous rehabilitation pathway for patients, potentially reducing reliance on traditional clinic visits.